Authors
Latest:
Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLCVilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.
Latest:
UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in MiceUCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling
Latest:
New California Tobacco Cessation Policy Research Center to be Housed at Cancer CenterUC Davis Comprehensive Cancer Center has launched the state’s first-ever Tobacco Cessation Policy Research Center.
Latest:
Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple MyelomaYael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Latest:
Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 VaccinesRenold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.
Latest:
Exploring Real-World Evidence Presented at ATA 2023Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Latest:
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCLHayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.
Latest:
Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal CancerNoam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.
Latest:
Dr Lee on Tremelimumab Plus Durvalumab in Ovarian CancerJung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.
Latest:
Missing a Rare Cause of Hereditary CancerNew research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.
Latest:
Nerlakanti on the Role of HDAC Inhibitors in OsteosarcomaNiveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.
Latest:
Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple MyelomaFenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.
Latest:
Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple MyelomaTarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.
Latest:
Dr. Harris on Remaining Questions With Treatment Sequencing in HCCWilliam P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.
Latest:
Dr. Awad on Objectives of the Phase 2 GEOMETRY Mono-1 Study in NSCLCMark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).
Latest:
Dr Stewart on the Multiomic Landscape of Squamous Cell Lung CancerPaul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.
Latest:
Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial CancerVikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.
Latest:
Dr Ackroyd on the Assessment of Time Toxicity in Advanced/Recurrent Endometrial CancerSarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.
Latest:
Future of MFExperts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.
Latest:
Dr. Sia on a Novel Classification System in Intrahepatic CholangiocarcinomaDaniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.
Latest:
Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple MyelomaMansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast CancerSara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.
Latest:
Dr. Lee on the Importance of Collaboration in Precision MedicineKelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.
Latest:
Dr. Strickland on the Diagnosis of ESCCStephen A. Strickland, MD, MSCI, discusses a step-by-step approach for the diagnosis and workup of esophageal squamous cell carcinoma.
Latest:
Practical Advice on the Use of ctDNA Testing in Breast CancerClosing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.
Latest:
Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETsDaneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.
Latest:
Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple MyelomaDoris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.
